The effect of competitive antagonist chain length on NMDA receptor subunit selectivity

Bihua Feng, Richard M. Morley, David E. Jane, Daniel T. Monaghan

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The widely-used N-methyl-d-aspartate (NMDA) receptor antagonists (R)-4-(3-phosphonopropyl) piperazine-2-carboxylic acid ((R)-CPP) and (R)-2-amino-7-phosphonoheptanoate ((R)-AP7) are frequently used as general NMDA receptor antagonists and assumed not to display significant selectivity among NMDA receptor NR2 subunits. However, electrophysiological studies have suggested that certain longer chain N-methyl-d-aspartate (NMDA) receptor competitive antagonists, such as (R)-CPP are ineffective at subpopulations of NMDA receptors in the red nucleus, superior colliculus, and hippocampus. Using recombinant receptors expressed in Xenopus oocytes, we have examined the effect of antagonist chain length on NR2 subunit selectivity. All antagonists displayed the potency order (high to low affinity) of NR2A > NR2B > NR2C > NR2D, however the longer chain antagonists (having 7 instead of 5 bond lengths between acidic groups) displayed much greater subunit selectivity than their short-chain homologues. For example (R)-CPP displayed a 50-fold difference in affinity between NR2A-containing and NR2D-containing NMDA receptors, while the shorter chain homologue 4-(phosphonomethyl) piperazine-2-carboxylic acid (PMPA) displayed only a 5-fold variation in affinity. These results can account for the earlier physiological findings and suggest that longer chain antagonists such as (R)-CPP and (R)-AP7 should not be used as general NMDA receptor antagonists.

Original languageEnglish (US)
Pages (from-to)354-359
Number of pages6
JournalNeuropharmacology
Volume48
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Red Nucleus
Superior Colliculi
Xenopus
aspartic acid receptor
Oocytes
Hippocampus
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
piperazine-2-carboxylic acid

Keywords

  • Antagonist
  • CPP
  • Glutamate
  • NMDA
  • NR2
  • Xenopus oocytes

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. / Feng, Bihua; Morley, Richard M.; Jane, David E.; Monaghan, Daniel T.

In: Neuropharmacology, Vol. 48, No. 3, 03.2005, p. 354-359.

Research output: Contribution to journalArticle

Feng, Bihua ; Morley, Richard M. ; Jane, David E. ; Monaghan, Daniel T. / The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. In: Neuropharmacology. 2005 ; Vol. 48, No. 3. pp. 354-359.
@article{b8ddd6d65f0a4d0ebbf6dc9e28f7e39e,
title = "The effect of competitive antagonist chain length on NMDA receptor subunit selectivity",
abstract = "The widely-used N-methyl-d-aspartate (NMDA) receptor antagonists (R)-4-(3-phosphonopropyl) piperazine-2-carboxylic acid ((R)-CPP) and (R)-2-amino-7-phosphonoheptanoate ((R)-AP7) are frequently used as general NMDA receptor antagonists and assumed not to display significant selectivity among NMDA receptor NR2 subunits. However, electrophysiological studies have suggested that certain longer chain N-methyl-d-aspartate (NMDA) receptor competitive antagonists, such as (R)-CPP are ineffective at subpopulations of NMDA receptors in the red nucleus, superior colliculus, and hippocampus. Using recombinant receptors expressed in Xenopus oocytes, we have examined the effect of antagonist chain length on NR2 subunit selectivity. All antagonists displayed the potency order (high to low affinity) of NR2A > NR2B > NR2C > NR2D, however the longer chain antagonists (having 7 instead of 5 bond lengths between acidic groups) displayed much greater subunit selectivity than their short-chain homologues. For example (R)-CPP displayed a 50-fold difference in affinity between NR2A-containing and NR2D-containing NMDA receptors, while the shorter chain homologue 4-(phosphonomethyl) piperazine-2-carboxylic acid (PMPA) displayed only a 5-fold variation in affinity. These results can account for the earlier physiological findings and suggest that longer chain antagonists such as (R)-CPP and (R)-AP7 should not be used as general NMDA receptor antagonists.",
keywords = "Antagonist, CPP, Glutamate, NMDA, NR2, Xenopus oocytes",
author = "Bihua Feng and Morley, {Richard M.} and Jane, {David E.} and Monaghan, {Daniel T.}",
year = "2005",
month = "3",
doi = "10.1016/j.neuropharm.2004.11.004",
language = "English (US)",
volume = "48",
pages = "354--359",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - The effect of competitive antagonist chain length on NMDA receptor subunit selectivity

AU - Feng, Bihua

AU - Morley, Richard M.

AU - Jane, David E.

AU - Monaghan, Daniel T.

PY - 2005/3

Y1 - 2005/3

N2 - The widely-used N-methyl-d-aspartate (NMDA) receptor antagonists (R)-4-(3-phosphonopropyl) piperazine-2-carboxylic acid ((R)-CPP) and (R)-2-amino-7-phosphonoheptanoate ((R)-AP7) are frequently used as general NMDA receptor antagonists and assumed not to display significant selectivity among NMDA receptor NR2 subunits. However, electrophysiological studies have suggested that certain longer chain N-methyl-d-aspartate (NMDA) receptor competitive antagonists, such as (R)-CPP are ineffective at subpopulations of NMDA receptors in the red nucleus, superior colliculus, and hippocampus. Using recombinant receptors expressed in Xenopus oocytes, we have examined the effect of antagonist chain length on NR2 subunit selectivity. All antagonists displayed the potency order (high to low affinity) of NR2A > NR2B > NR2C > NR2D, however the longer chain antagonists (having 7 instead of 5 bond lengths between acidic groups) displayed much greater subunit selectivity than their short-chain homologues. For example (R)-CPP displayed a 50-fold difference in affinity between NR2A-containing and NR2D-containing NMDA receptors, while the shorter chain homologue 4-(phosphonomethyl) piperazine-2-carboxylic acid (PMPA) displayed only a 5-fold variation in affinity. These results can account for the earlier physiological findings and suggest that longer chain antagonists such as (R)-CPP and (R)-AP7 should not be used as general NMDA receptor antagonists.

AB - The widely-used N-methyl-d-aspartate (NMDA) receptor antagonists (R)-4-(3-phosphonopropyl) piperazine-2-carboxylic acid ((R)-CPP) and (R)-2-amino-7-phosphonoheptanoate ((R)-AP7) are frequently used as general NMDA receptor antagonists and assumed not to display significant selectivity among NMDA receptor NR2 subunits. However, electrophysiological studies have suggested that certain longer chain N-methyl-d-aspartate (NMDA) receptor competitive antagonists, such as (R)-CPP are ineffective at subpopulations of NMDA receptors in the red nucleus, superior colliculus, and hippocampus. Using recombinant receptors expressed in Xenopus oocytes, we have examined the effect of antagonist chain length on NR2 subunit selectivity. All antagonists displayed the potency order (high to low affinity) of NR2A > NR2B > NR2C > NR2D, however the longer chain antagonists (having 7 instead of 5 bond lengths between acidic groups) displayed much greater subunit selectivity than their short-chain homologues. For example (R)-CPP displayed a 50-fold difference in affinity between NR2A-containing and NR2D-containing NMDA receptors, while the shorter chain homologue 4-(phosphonomethyl) piperazine-2-carboxylic acid (PMPA) displayed only a 5-fold variation in affinity. These results can account for the earlier physiological findings and suggest that longer chain antagonists such as (R)-CPP and (R)-AP7 should not be used as general NMDA receptor antagonists.

KW - Antagonist

KW - CPP

KW - Glutamate

KW - NMDA

KW - NR2

KW - Xenopus oocytes

UR - http://www.scopus.com/inward/record.url?scp=13844253597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844253597&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2004.11.004

DO - 10.1016/j.neuropharm.2004.11.004

M3 - Article

C2 - 15721167

AN - SCOPUS:13844253597

VL - 48

SP - 354

EP - 359

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 3

ER -